Global Health Ltd

Stage 2 · Advancing · week 15Setup 4.4 WatchSolid +0.8

As of 9 Oct 2026, Global Health is in Stage 2 — advancing, the uptrend phase, in week 15 (since 25 Jun 2026). It closed at ₹1,313, 13.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Global Health Limited, together with its subsidiaries, provides healthcare services in India. More about the company

₹1,312.7
+2.84% today
₹35,275 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dHospitals & Diagnostic Centres 32.3%-6.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

4.4 Watch

Momentum

Steady

Edge

Solid +0.8

Setup-score rank among Stage 2 peers: #5 of 10 in Hospitals & Diagnostic Centres · #51 of 78 in Health Care

Is MEDANTA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-13.0%
₹961.1 lo₹1,508.9 hi
13.0% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 15
1w13w26w
Week 15 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
5.9%
200 DMA: ₹1,239.3 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.83x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -3.4% vs MA50 +1.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-8.1%
3M
-1.8%
6M
+24.0%
YTD
+10.5%
1Y
+0.6%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #55 of 74 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Hospitals & Diagnostic Centres
↓ Peaking
Stage 2%
32.3%
20d Δ
-6.5pp
1M return
-8.1%
3M return
-10.8%
Industry Stage-2 % · last 20 days
Ranks #7 of 9 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 38w
S3 14w
S4 14w
S2 15w
S4 20w
S2 15w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 8w → S2 38w → S3 14w → S4 14w → S1 7w → S4 4w → S1 4w → S2 12w → S3 5w → S2 15w → S3 5w → S4 20w → S1 6w → S2 15w current
Total tracked: 168 weeks across 14 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-25
3 appearances in last 60 days. First seen: 2025-03-25.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 15 · Vol 0.83x
2026-10-08S2
Wk 15 · Vol 0.51x
2026-10-07S2
Wk 15 · Vol 1.65x
2026-10-06S2
Wk 15 · Vol 1.37x
2026-10-05S2
Wk 15 · Vol 0.78x
2026-10-01S2
Wk 14 · Vol 1.25x
2026-09-30S2
Wk 14 · Vol 1.61x
2026-09-29S2
Wk 14 · Vol 0.73x
2026-09-28S2
Wk 14 · Vol 0.42x
2026-09-25S2
Wk 14 · Vol 0.57x
2026-09-24S2
Wk 13 · Vol 0.62x
2026-09-23S2
Wk 13 · Vol 0.28x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,426.5
200 DMA
₹1,239.3
52W High
₹1,508.9
52W Low
₹961.1
5D Low
₹1,276.5
Resistance levels (recent highs)
20d High
₹1,506.2
60d High
₹1,508.9
120d High
₹1,508.9
250d High
₹1,508.9
Next resistance
+14.7%
to 20d High
Ask the Market AI about MEDANTAAsk →
P/E (TTM)
58.5
Forward 37.4
Earnings Growth (YoY)
+42.0%
Revenue +24.5%
ROE
+15.0%
Profit margin +12.6%
Dividend Yield
0.04%
P/B 8.8
About this companyHealth Care· Hospitals & Diagnostic Centres

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.